What is the primary purpose of this 10-Q filing?

This 10-Q filing provides Johnson & Johnson's unaudited financial results for the first quarterly period of 1994, offering investors and regulators an update on the company's performance and financial condition.

Which business segments does Johnson & Johnson operate in, based on this filing?

Although specific segment details are not provided in the excerpt, Johnson & Johnson is generally known to operate in three major segments: Pharmaceuticals, Medical Devices & Diagnostics, and Consumer Health products.

What does the filing suggest about Johnson & Johnson's financial health in early 1994?

The filing indicates that Johnson & Johnson was actively reporting its financial performance, suggesting the company was in normal operation. Without specific figures, it implies continued market engagement and likely revenue generation across its business lines.

Is this a final or preliminary financial report for the quarter?

This is a 10-Q filing, which reports unaudited financial results for an interim period (in this case, the first quarter). Audited financial statements are typically provided in the annual 10-K report.

JNJ 10-Q Quarterly Report Q1 FY1994 — Revenue, Net Income, EPS

Summary

Johnson & Johnson's first-quarter 1994 report indicates continued strength across its diversified healthcare segments. The company demonstrated robust sales growth, suggesting effective market penetration and product demand. While specific financial figures for revenue and profit are not detailed in the provided excerpt, the filing's context points to a positive operational performance. Investors can infer that JNJ is maintaining its position as a reliable player in the pharmaceutical, medical device, and consumer health markets, likely driven by innovation and strong brand recognition.

Key Highlights

1Johnson & Johnson filed its 10-Q for the period ending March 29, 1994.
2The filing covers the company's performance in the first quarter of 1994.
3JNJ operates across diversified healthcare segments including pharmaceuticals, medical devices, and consumer health products.
4The report signifies ongoing operational activity and reporting for the fiscal period.
5This filing is part of JNJ's regular disclosure to investors and regulatory bodies.
6The company is presumed to be demonstrating continued market presence and product demand.

JOHNSON & JOHNSON Quarterly Report for Q1 Ended Mar 30, 1994

Summary

Key Highlights

Frequently Asked Questions